AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: SOLIRIS (Alexion Pharmaceuticals) (soliris.net)
Soliris.net is a high-substance clinical site that technically underperforms by omitting structured data and direct proof paths. It currently functions less as a standalone drug resource and more as a transition portal for Ultomiris, creating moderate semantic inconsistency.
Implement Product and Organization schema to provide technical authority to search engines. Replace the fluff heading Tried. Tested. Proven. with a specific metric regarding clinical efficacy or patient outcomes. Add a dedicated Clinical Evidence section with direct outbound links to ClinicalTrials.gov for the referenced 50 studies. Clarify the relationship between Soliris and Ultomiris on the homepage to reduce the sense of bait-and-switch drift on indication pages.
Information density is exceptionally high due to the clinical nature of the product. While the H2 Tried. Tested. Proven. is a high-fluff power phrase, the body text is saturated with technical substance such as anti-AChR antibody-positive and complement-mediated thrombotic microangiopathy. The site provides specific counts (50 clinical trials, 15 years postmarket) rather than vague longevity claims.
Parameter drift, trailing slash inconsistencies, and language leaks create unintended alternate identities. Get a Clinical Canonical Diagnosis to reveal where duplicate embeddings are silently created.
There is a notable strategic semantic drift between the homepage and sub-pages. The homepage presents Soliris as the primary focus, but sub-pages (aHUS and PNH) immediately pivot to promoting a different drug, ULTOMIRIS, as a transition or superior option. This creates a disconnect where a brand-specific domain (soliris.net) serves primarily as a migration funnel for a successor product.
Transition from a collection of strings to a machine verifiable identity. Generate your Clinical SEO Strategy to establish a robust Knowledge Graph Topology and eliminate semantic black holes.
The site avoids standard trust theatre like unverified customer reviews (review_count 0). However, it makes significant claims about being studied in over 50 clinical trials without providing a direct proof path or external links to those studies (proof_links_count 0). The reliance on internal brochures rather than external peer-reviewed citations in the crawl data constitutes a proof gap.
The ratio of substance to fluff is high, but the ratio of verifiable evidence (external links) to assertions is low. The site relies on the user trusting the FDA-approved status as the ultimate proof, which allows it to omit granular data summaries. For every 5 technical assertions about indications, there is 0 direct outbound links to independent clinical validation in the provided data.
To examine how structural entropy affects chunking and retrieval, review the Moz Semantic HTML audit. View the Moz Semantic HTML Audit for a complete example of heading logic, landmark integrity, and DOM depth diagnostics.
The site uses several industry clichés such as Tried. Tested. Proven. and furthering commitment to patients. The Personalized Patient Support and Take an active role sections are boilerplate pharma templates. Despite this, the value proposition is unique to the specific biological mechanism of the drug, preventing it from being entirely commoditized.
There is a significant technical authority gap as the site lacks any structured data (schema_json is null). For a multi-billion dollar pharmaceutical brand, the absence of Organization or Product schema is a major technical oversight. Furthermore, reference to Alexion Nurse Case Managers provides no verifiable digital footprint or professional credentials for the individuals involved.
The marketing tone of Tried. Tested. Proven. is backed by the mention of 50 trials, but the site fails to display actual data points from those trials in the text. There is a disconnect between the claim of 15 years of experience and the lack of specific real-world evidence metrics beyond general safety warnings. Most clinical claims are buried in downloadable brochures rather than being transparently proved on the page.
Medical Devices, Pharma & Biotech BS: SOLIRIS (Alexion Pharmaceuticals) (soliris.net)
The content perfectly aligns with the Pharma and Biotech industry, characterized by high-density regulatory disclosures, Boxed Warnings, and specific clinical indications. The presence of detailed safety protocols and REMS program information confirms this is a legitimate medical product site.
The access layer decides whether your content even enters the model's world. Review the Crawlability & Indexation Framework to see how AI visible content differs from what humans see in the browser.
“The score of 33 is driven largely by technical identity gaps (Step 5) and the lack of external proof paths (Step 3). While the medical content is dense and substantively accurate, the site's strategic shift toward a different product on its sub-pages creates a unique form of semantic drift that slightly inflates the BS score.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 24, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at SOLIRIS (Alexion Pharmaceuticals) to view the most current version of their content and see directly what the company offers.